Procedural success and 30-day clinical outcomes after percutaneous aortic valve replacement using current third-generation self-expanding corevalve prosthesis

Journal of Invasive Cardiology

Volumn 21, Issue 3, 2009, Pages 93-98

  Tamburino, Corrado ^a   Capodanno, Davide ^a   Mul̀e, Massimiliano ^a   Scarabelli, Marilena ^a   Cammalleri, Valeria ^a   Barbanti, Marco ^a   Calafiore, Antonio ^a   Ussia, Gianpaolo ^a  

^a Ospedale Ferrarotto   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CLOPIDOGREL; HEPARIN;

AGED; ANTIBIOTIC THERAPY; AORTA STENOSIS; AORTA VALVE REPLACEMENT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART TAMPONADE; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HIGH RISK PATIENT; HUMAN; IMPLANTATION; LOADING DRUG DOSE; MALE; SCREENING; SEX DIFFERENCE; SHORT COURSE THERAPY; SURGICAL MORTALITY; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AORTIC VALVE; AORTIC VALVE STENOSIS; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TREATMENT OUTCOME;

EID: 67649576622     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rajamannan NM, Bonow RO, Rahimtoola SH. Calcific aortic stenosis: An update. Nat Clin Pract Cardiovasc Med. 2007;4:254-262.
2. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: A population-based study. Lancet 2006;368:1005-1011.
3. Vahanian A, Baumgartner H, Bax J, et al; Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007;28:230-268.
4. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the Society of Cardiovascular Anesthesiologists: Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006;114:e84-e231.
5. Iung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: Why are so many denied surgery? Eur Heart J 2005;26:2714-2720.
6. Cribier A, Eltchaninoff H, Tron C, et al. Treatment of calcific aortic stenosis with the percutaneous heart valve: Mid-term follow-up from the initial feasibility studies: The French experience. J Am Coll Cardiol 2006;47:1214-1223.
7. Grube E, Laborde JC, Gerckens U, et al. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: The Siegburg first-in-man study. Circulation 2006;114:1616-1624.
8. Grube E, Schuler G, Buellesfeld L, et al. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: Device success and 30-day clinical outcome. J Am Coll Cardiol 2007;50:69-76.
9. Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) CoreValve ReValving System: Results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroInterv 2008;4:242-249.
10. Roques F, Nashef SA, Michel P, et al. Risk factors and outcome in European cardiac surgery: Analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999;15:816-822.
11. Laborde JC, Borenstein N, Behr L, et al. Percutaneous implantation of the CoreValve aortic valve prosthesis for patients presenting high risk for surgical valve replacement. Eurointerv 2006;1:472-474.
12. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: First human case description. Circulation 2002;106:3006-3008.
13. Cribier A, Eltchaninoff H, Tron C, et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol 2004;43:698-703.
14. Grube E, Laborde JC, Zickmann B, et al. First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis. Catheter Cardiovasc Interv 2005;66:465-469.
15. Webb JG, Pasupati S, Humphries K, et al. Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation 2007;116:755-763.
16. Marcheix B, Lamarche Y, Berry C, et al. Surgical aspects of endovascular retrograde implantation of the aortic CoreValve bioprosthesis in high-risk older patients with severe symptomatic aortic stenosis. J Thorac Cardiovasc Surg 2007;134:1150-1156.